Progressive Supranuclear Palsy (Psp) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Progressive Supranuclear Palsy (PSP), also known as Steele-Richardson-Olszewski syndrome, is a rare neurodegenerative disorder characterized by progressive loss of voluntary
eye movements, postural instability, akinesia, and cognitive impairment. It is classified as a tauopathy, sharing pathological features with Alzheimer's Disease and Corticobasal Degeneration.[1]
Progressive Supranuclear Palsy is a rapidly progressive neurological disorder that affects brain regions controlling movement, cognition, and eye movements. The disease was first
described by John Steele, John Richardson, and Jerzy Olszewski in 1964.[1] PSP affects approximately 5-6 per 100,000 individuals worldwide, with an estimated 20,000-30,000 cases in
the United States.[2] The typical onset occurs in the sixth or seventh
decade of life, with most patients developing symptoms between ages 50-70.[2]
The pathophysiology of PSP involves accumulation of abnormal tau] protein in the brain, forming neurofibrillary tangles that lead to neuronal dysfunction and cell death. class="ref-link" data-ref-number="3" data-ref-text="Holness LK, Lang AE. Progressive Supranuclear Palsy: emerging disease mechanisms and therapeutic strategies.
Nat Rev Neurol. 2024;20(5):279-294." title="Holness LK, Lang AE. Progressive Supranuclear Palsy: emerging disease mechanisms and therapeutic strategies. Nat Rev Neurol.
2024;20(5):279-294.">3 The disease primarily affects the basal ganglia, brainstem, and frontal lobes.[9]
Supranuclear Ophthalmoplegia
The hallmark feature of PSP is progressive limitation of vertical gaze, particularly downward gaze.[5] Patients initially experience difficulty looking down while reading or descending
stairs. Horizontal eye movements become progressively impaired, leading to a characteristic "staring" appearance. Patients compensate by moving their entire head to track objects.
Postural Instability
Severe postural instability develops early in the disease, leading to frequent falls.[5] Patients typically fall backward and have particular difficulty negotiating turns. This symptom often
appears within the first year of disease onset and significantly impacts quality of life.[5]
Akinesia and Bradykinesia
Patients exhibit progressive slowing of voluntary movements (bradykinesia) and reduced ability to initiate movement (akinesia). Unlike Parkinson's Disease, tremor is typically
absent or mild in PSP.[5]
Rigidity
Axial rigidity (neck and trunk stiffness) is prominent and often more severe than limb rigidity. This leads to a characteristic posture with neck extension (retrocollis) and
upright positioning.[5]
Frontal Lobe Dysfunction
Executive dysfunction is nearly universal in PSP, including impaired planning, decision-making, and problem-solving.[1] Patients demonstrate reduced verbal fluency and difficulty
with tasks requiring cognitive flexibility.
Behavioral Changes
Speech and Swallowing Dysarthria
Progressive speech difficulty is common, characterized by a slow, monotone, and often slurred speech pattern.[5] Dysphagia (swallowing difficulties) develops in most patients and poses significant
aspiration risk.[5]
PSP is classified as a primary tauopathy, meaning it is characterized by abnormal accumulation of the microtubule-associated protein tau in neurons and glia. class="ref-link" data-ref-number="3" data-ref-text="Holness LK, Lang AE. Progressive Supranuclear Palsy: emerging disease mechanisms and therapeutic strategies.
Nat Rev Neurol. 2024;20(5):279-294." title="Holness LK, Lang AE. Progressive Supranuclear Palsy: emerging disease mechanisms and therapeutic strategies. Nat Rev Neurol.
2024;20(5):279-294.">3 In PSP, hyperphosphorylated tau protein forms insoluble aggregates called neurofibrillary tangles (NFTs) and tufted astrocytes. class="ref-link" data-ref-number="4" data-ref-text="Kovacs GG, Ferrer I, Grinberg LT, et al. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation
strategy. Acta Neuropathol. 2023;145(1):1-20." title="Kovacs GG, Ferrer I, Grinberg LT, et al. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta
Neuropathol. 2023;145(1):1-20.">4
The distribution of tau pathology in PSP follows a characteristic pattern:[9]
While most cases of PSP are sporadic, genetic factors play a role in disease risk:[3]
MAPT Gene Mutations
The microtubule-associated protein tau (MAPT) gene on chromosome 17q21 is the major genetic contributor to PSP.[3] The H1
haplotype of MAPT is strongly associated with increased PSP risk.[3] Certain specific mutations (such as P301L) can cause familial PSP presentations.
| Feature | PSP | Parkinson's Disease | Corticobasal Degeneration |
|---|---|---|---|
| Eye movements | Vertical gaze palsy | Usually normal | Variable |
| Tremor | Rare | Common | Uncommon |
| Postural instability | Early, frequent falls | Later | Variable |
| Response to levodopa | Poor | Good | Poor |
| Tau pathology | 4R tau | alpha-synuclein | 4R tau |
Imaging
CSF and Blood Biomarkers
Tau-Targeting Therapies
Symptomatic Treatments
Physical Therapy
Speech Therapy
Occupational Therapy
PSP is rapidly progressive, with median survival of 5-8 years from symptom onset.[8] The disease progresses more rapidly than Parkinson's Disease.
Research focuses on identifying reliable biomarkers for PSP:[10]
Active clinical trials are investigating:[6]
The study of Progressive Supranuclear Palsy (Psp) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.